K

Kyowa Kirin

Global specialty pharma focused on antibodies

Associate Director - Data Governance, Commercial Operations

Full-TimeUpdated on 10/23/2026
$166.7k - $215.7k+ Annual bonus program + Long-term incentive program
Expert
Bachelor's, Master's
Princeton, NJ, USA
In PersonUp to 10% domestic travel.
Data & AnalyticsData Management

About the job

Requirements
  • A bachelor's degree in a relevant field such as Data Science, Business Analytics, Information Systems, Life Sciences, or equivalent is required.
  • Eight to ten or more years of experience in data management, data governance, data catalog, or data stewardship, with a significant portion in the pharmaceutical, biotech, or life sciences industry.
  • Experience supporting or operating a data governance committee, data council, or cross-functional steering group, including charter design, agenda facilitation, decision documentation, and action tracking.
  • Experience building or leading an enterprise data governance program from an early stage, including framework design, policy and standard operating procedure authorship, data ownership models, and adoption across functions without direct reporting authority.
  • Experience maintaining a data catalog or metadata management platform such as Collibra, Alation, Informatica, Microsoft Purview, or Unity Catalog.
  • Experience designing and implementing data access governance processes, including role-based access models, tiered access frameworks, and periodic access audits, in partnership with technical provisioning teams.
  • Experience defining canonical business metric definitions and reconciling conflicting definitions across commercial and non-commercial stakeholders.
  • Experience establishing data quality management practices, including scorecards, thresholds, severity-based issue triage, and remediation tracking for third-party and internally generated data assets.
  • Deep understanding of pharmaceutical data domains.
  • Knowledge of HIPAA, personally identifiable information, protected health information handling requirements, and pharmaceutical industry data privacy and compliance standards, with experience establishing durable data boundary rules in partnership with Legal, Privacy, and Compliance.
  • Ability to communicate with technical and business audiences and translate data infrastructure and governance decisions into plain-language guidance business stakeholders can act on.
  • Strong written communication skills, including the ability to produce standard operating procedures, data governance policies, data dictionaries, and business-facing reference documents.
  • Ability to lead cross-functional change initiatives and drive results through influence, stakeholder relationships, and clear communication rather than direct authority.
  • Ability to organize, prioritize, meet deadlines, make decisions, and change course quickly.
  • Ability to maintain a firm position on governance standards while building working relationships across functions.
  • Ability to work with ambiguity in a dynamic, fast-paced, high-growth environment and demonstrate cultural sensitivity and consensus-building in a multinational organization.
Responsibilities
  • Serve as the first point of contact for data access requests by triaging and classifying requests by data sensitivity, routing them to the appropriate Domain Data Owner, and tracking them through technical provisioning by the Data Platform team.
  • Maintain and publish data access request standard operating procedures that define compliance and legal review at the policy level.
  • Administer a tiered access model across enterprise data lake environments for data scientists, analysts, business users, and external partners.
  • Conduct quarterly access audits to identify and coordinate removal of stale or excess access.
  • Maintain a complete, documented access log across data lake workspaces, including the rationale for each grant and defined expiration dates.
  • Draft, maintain, and publish enterprise data governance standard operating procedures covering access requests, patient data boundary rules, new data source onboarding, data quality escalation, and incident response.
  • Own the operational cadence of the Data Management Committee, including agendas, minutes, action tracking, and the enterprise governance policy register, and prepare materials and recommendations for quarterly committee sessions.
  • Document end-to-end lineage for critical datasets from source system through ingestion to downstream reporting and analytics, in partnership with technical owners.
  • Serve as a senior escalation point for data governance disputes, access conflicts, and policy interpretations across commercial, medical, market access, and patient services functions.
  • Define and maintain the Domain Data Owner model, including assignments, accountabilities, and operating expectations.
  • Oversee compliant acquisition, use, and stewardship of data assets by coordinating with legal, procurement, and business stakeholders on contractual, privacy, and data-use requirements.
  • Lead intake and assessment of new data sources entering the enterprise data lake, including business justification, compliance and privacy review, Domain Data Owner assignment, and Data Management Committee notification, with technical assessment provided by the Data Platform and Data Architecture teams.
  • Ensure every new source has a documented owner, defined refresh service-level agreement, data quality baseline, and catalog entry before promotion to production and downstream consumption.
  • Partner with Data Platform vendors, IT, and external vendors to ensure appropriate controls and quality standards from data ingestion through downstream consumption.
  • Own and maintain the enterprise data catalog across the enterprise data lake, legacy Synapse platform, and connected source systems, including business descriptions, data owners, refresh frequency, granularity, and access tier.
  • Document business-friendly metadata for active datasets and enforce consistent metadata standards across the organization.
  • Build and maintain the enterprise business glossary of canonical definitions for key metrics and drive cross-functional alignment and formal approval.
  • Partner with Data Platform and Data Architecture teams to rationalize the schema catalog and coordinate archiving of inactive or redundant schemas from completed projects.
  • Coordinate glossary and data model alignment with the canonical data model initiative and downstream analytics and reporting teams.
  • Establish and maintain a data quality scorecard for priority datasets, including specialty pharmacy and distributor feeds, claims, payer policy, tokenized data, and customer relationship management data, tracking accuracy, completeness, and timeliness.
  • Own data quality issue intake by receiving business user reports, triaging by severity, routing to technical owners, and tracking resolution.
  • Monitor critical vendor data delivery service-level agreements and escalate failures through defined channels; ensure vendor accountability and corrective action for breaches.
  • Publish a quarterly data quality scorecard to the Data Management Committee and Domain Data Owners.
  • Lead P1 incident retrospectives, documenting root causes, remediation actions, and process changes to prevent recurrence.
  • Act as primary liaison between commercial, medical, market access, and patient services teams and the Data Platform and IT functions, translating requirements and governance decisions into actionable outcomes.
  • Develop and maintain function-specific data consumer guides explaining available data, access request processes, and points of contact.
  • Run onboarding for new enterprise data lake users so they understand the catalog, available data assets, access tiers, and governance expectations before access is provisioned.
  • Host monthly data office hours for business stakeholders to raise data questions, access requests, quality feedback, and glossary input.
  • Define, track, and report enterprise data governance metrics, including data quality performance, issue resolution time, access request cycle time, catalog coverage, and adoption of governed definitions.
  • Champion a data-first mindset across the commercial organization while balancing accessibility and innovation with governance, accountability, and measurable business value.
Desired Qualifications
  • A master's degree is preferred.
  • A Certified Data Management Professional, DCAM, DAMA, or equivalent data governance certification is preferred.
  • Working familiarity with cloud data lake or data warehouse environments such as Azure Databricks, Snowflake, Azure Synapse, or equivalent, sufficient to navigate the environment and participate credibly in technical discussions.
  • Working SQL proficiency sufficient to independently review data structures, validate definitions, and assess data quality issues before routing them to a technical owner.
  • Conceptual understanding of master data management and entity resolution, including matching, de-duplication, survivorship, and hierarchy management, as applied to healthcare professional, healthcare organization, and patient data domains.
  • Conceptual understanding of row-level and column-level security, role-based access control, and data classification models sufficient to define access tiers for technical implementation.
  • Familiarity with data integration concepts and tools such as Azure Data Factory or Informatica, sufficient to assess ingestion design against governance, documentation, and quality standards.
  • Familiarity with business intelligence and reporting tools such as Power BI, Tableau, or Qlik for governance reporting and data quality scorecarding.
  • Familiarity with patient tokenization and de-identification approaches such as Datavant and the governance implications of linking tokenized patient data to commercial datasets.
  • Working familiarity with artificial intelligence and machine learning governance concepts, including feature governance and reusable feature definitions, model input lineage, model monitoring and drift awareness, responsible artificial intelligence and human review expectations, and controls for protected health information and personally identifiable information, consent, bias, explainability, auditability, and governed use of next-best-action, next-best-customer, patient risk, churn, recommender, natural language processing insight extraction, and engagement propensity models.

About the company

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for its PreCheck Pilot Program on June 30, 2026.
  • Kyowa Kirin signed a U.S. access deal August 31, 2026, deferring Section 232 tariffs.
  • Pipeline remains active: KHK4951, OTL-203, and ziftomenib all advanced in 2026.

What critics are saying

  • Rocatinlimab died March 3, 2026 after Kaposi's sarcoma signals and trial termination.
  • Kyowa Kirin faces patent cliffs: major products lose protection in 2032 and 2033.
  • Sanford's $530 million build concentrates execution risk until FDA-ready production starts in 2027.

What makes Kyowa Kirin unique

  • Kyowa Kirin owns antibody, fermentation, and rare-disease manufacturing expertise since 1949.
  • The Sanford, North Carolina plant becomes its first U.S. biologics site, operational 2027.
  • Ziftomenib outside the U.S. gives Kyowa Kirin global AML rights through 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Hybrid Work Options
  • Pet Insurance

Growth & Insights and Company News

6 month growth

-2%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

PR Newswire
Dec 15th, 2025
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors

/PRNewswire/ -- Link Cell Therapies ("Link"), an oncology cell therapy company, today announced its official launch from stealth with a $60 million Series A...

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding